Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Virology

• Publication date

  2005-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.79.8.5232-5237.2005PMID 15795308PMCID PMC1069558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutralization of Animal Viruses

  2008cited by this paper
• The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope

  2004cited by this paper
• The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection

  2004cited by this paper
• Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1

  2003cited by this paper
• Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS

  2003cited by this paper
• Evidence for CD4-enchanced Signaling through the Chemokine Receptor CCR5*

  2003cited by this paper
• The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120

  2002cited by this paper
• Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

  2002cited by this paper
• Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate

  2001cited by this paper
• V3-Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1

  2001cited by this paper
• Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

  2001cited by this paper
• Identification of gp120 Regions Targeted by a Highly Potent Neutralizing Antiserum Elicited in a Chimpanzee Inoculated with a Primary Human Immunodeficiency Virus Type 1 Isolate

  2000cited by this paper
• Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M

  2000cited by this paper
• V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies

  2000cited by this paper
• Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins

  1999cited by this paper
• Constitutive cell surface association between CD4 and CCR5.

  1999cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.

  1998cited by this paper
• An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades

  1998cited by this paper
• Human Immunodeficiency Virus (HIV) Envelope Binds to CXCR4 Independently of CD4, and Binding Can Be Enhanced by Interaction with Soluble CD4 or by HIV Envelope Deglycosylation

  1998cited by this paper
• Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1

  1998cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

  1996cited by this paper
• Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

  1996cited by this paper
• Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.

  1995cited by this paper
• Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.

  1995cited by this paper
• Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry

  1995cited by this paper
• Antibody-antigen interactions: new structures and new conformational changes.

  1994cited by this paper
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994influential reference
• Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses

  1994cited by this paper
• Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

  1994cited by this paper
• Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

  1994cited by this paper
• Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1

  1994cited by this paper
• Antibody-antigen interactions

  1994cited by this paper
• Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

  1993cited by this paper
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

  1993cited by this paper
• Neutralization of Animal Viruses

  1993cited by this paper
• Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop

  1993cited by this paper
• Antibody-antigen interactions

  1993cited by this paper
• Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

  1992cited by this paper
• Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region

  1992influential reference
• Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

  1992cited by this paper
• Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

  1991cited by this paper
• Prevention of HIV Infection by Passive Immunization with HIV Immunoglobulin

  1991cited by this paper
• Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

  1991cited by this paper
• An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

  1991cited by this paper
• Generation of human monoclonal antibodies to human immunodeficiency virus.

  1989cited by this paper

• HUMAN IMMUNODEFICIENCY VIRUS: ELUSIVE PERSPECTIVES AND NOVEL VACCINATION APPROACHES

  2025cites this paper
• Dissecting Uricase Immunogenicity: Unveiling the Role of Quaternary Epitopes through In Silico Analysis

  2024cites this paper
• Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.

  2024cites this paper
• Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells

  2023cites this paper
• Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies

  2022cites this paper
• Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin

  2022cites this paper
• Fight fire with fire: the need for a vaccine based on intrinsic disorder and structural flexibility

  2022cites this paper
• Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

  2022cites this paper
• Mapping the intellectual structure of the coronavirus field (2000–2020): a co-word analysis

  2021cites this paper
• Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces

  2021cites this paper
• Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

  2021cites this paper
• Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth

  2020cites this paper
• Broadly Neutralizing Antibodies against HIV: Back to Blood.

  2019cites this paper
• Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

  2019cites this paper
• Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine

  2019cites this paper
• Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity

  2017cites this paper
• Germline‐targeting immunogens

  2017cites this paper
• 10 HIV Envelope-Specific Antibody and Vaccine Efficacy

  2017cites this paper
• Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates

  2017cites this paper
• Modulating the Antigenicity and Immunogenicity of HIV-1 Envelope by a Conserved N-Linked Glycan

  2016cites this paper
• Immunity to HIV

  2016cites this paper
• Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking

  2016cites this paper
• Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits

  2016cites this paper
• Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry

  2016influential citation
• Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site

  2016cites this paper
• Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein

  2016cites this paper
• Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory

  2016cites this paper
• Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

  2016cites this paper
• Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity

  2015cites this paper
• Antibodies Targeting the Envelope of HIV-1

  2015cites this paper
• Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.

  2015cites this paper
• Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites

  2015cites this paper
• The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel

  2015cites this paper
• Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain’s exceptional capacity for sequence variation

  2014cites this paper
• The influence of HIV envelope glycosylation on adaptive immune response

  2014cites this paper
• Immunology and virology of HIV-1 infection in Cameroon

  2014cites this paper
• Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

  2014cites this paper
• Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV

  2014cites this paper
• The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development

  2014cites this paper
• HIV-1 Specific Antibody Titers and Neutralization among Chronically Infected Patients on Long-Term Suppressive Antiretroviral Therapy (ART): A Cross-Sectional Study

  2014cites this paper
• HIV-1 Envelope Proteins and V1/V2 Domain Scaffolds with Mannose-5 to Improve the Magnitude and Quality of Protective Antibody Responses to HIV-1*

  2014cites this paper
• Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study

  2014cites this paper
• Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops

  2014cites this paper
• Antibodiesand Their Recognition by Immunotypes of a Quaternary Site of HIV-1

  2014cites this paper
• Evaluating the neutralizing antibody response to HIV-1 membrane proximal external regional; Implications for vaccine design

  2014cites this paper
• Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12.

  2013cites this paper
• Novel HIV vaccine strategies: overview and perspective

  2013influential citation
• Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2

  2013cites this paper
• Nonhuman Primate Models for HIV/AIDS Vaccine Development

  2013cites this paper
• Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies

  2013cites this paper
• Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

  2013cites this paper
• Broadly neutralizing antiviral antibodies.

  2013cites this paper
• Antigenic Properties of the HIV Envelope on Virions in Solution

  2013cites this paper
• Mathematical models: a key to understanding HIV envelope interactions?

  2013influential citation
• HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

  2013cites this paper
• Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.).

  2013cites this paper
• 51 – Human immunodeficiency virus vaccines

  2013cites this paper
• Développement d'anticorps monoclonaux humains de type IgA dirigés contre la partie C-terminale de la protéine d'enveloppe gp41 du VIH-1

  2013cites this paper
• Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies

  2012cites this paper
• Human hybridoma technology

  2012cites this paper
• Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer

  2012cites this paper
• Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

  2012cites this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cites this paper
• Basic research in HIV vaccinology is hampered by reductionist thinking

  2012cites this paper
• 42. Catalytic Antibodies

  2012cites this paper
• HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120

  2012cites this paper
• Basic research in HIV vaccinology is hampered by reductionist thinking

  2012cites this paper
• The design and development of an HIV-1 vaccine to elicit a broadly neutralising antibody response

  2012cites this paper
• HIV vaccine design: the neutralizing antibody conundrum.

  2012cites this paper
• Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

  2012cites this paper
• Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding

  2012cites this paper
• Antibody–antigen pair probed by combinatorial approach and rational design: Bringing together structural insights, directed evolution, and novel functionality

  2012cites this paper
• The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

  2012cites this paper
• Role of Human Immunodeficiency Virus Type 1 Envelope Structure in the Induction of Broadly Neutralizing Antibodies

  2012cites this paper
• Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

  2012cites this paper
• HIV vaccine design based on in vivo evolution of quasispecies envelope proteins

  2012cites this paper
• Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies

  2011cites this paper
• Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals

  2011cites this paper
• Unusually Potent Neutralizing Activities Monoclonal Antibodies Possessing by Human and Rhesus Macaque of Related Quaternary Epitopes Recognized Diversity of Variable-Region Determinants Characterization of Structural Features and

  2011cites this paper
• Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

  2011influential citation
• Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer

  2011cites this paper
• Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine

  2011cites this paper
• Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

  2011cites this paper
• Limitations to the structure‐based design of HIV‐1 vaccine immunogens

  2011influential citation
• Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 (cid:1) †§

  2011influential citation
• Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities

  2011influential citation
• Binding Interactions between Soluble HIV Envelope Glycoproteins and Quaternary-Structure-Specific Monoclonal Antibodies PG9 and PG16

  2011cites this paper
• Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop

  2011cites this paper
• B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

  2011cites this paper
• Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies

  2011cites this paper
• Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

  2011cites this paper
• Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Virions

  2011cites this paper
• Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

  2011cites this paper
• HIV-1 Glycoprotein Immunogenicity

  2011cites this paper
• Neutralizing antibody responses and viral evolution in a longitudinal cohort of HIV subtype C infected antiretroviral-naïve individuals.

  2011cites this paper
• HIV Envelope-Specific Antibody and Vaccine Efficacy

  2011cites this paper
• Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.

  2011cites this paper
• Characterization of the vaginal microflora of HIV positive and HIV negative women in a sub-urban population of Kenya

  2011cites this paper
• Longitudinal Study of Primary HIV-1 Isolates in Drug-Naïve Individuals Reveals the Emergence of Variants Sensitive to Anti-HIV-1 Monoclonal Antibodies

  2011cites this paper
• Is developing an HIV-1 vaccine possible?

  2010cites this paper